Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis

Clinical Therapeutics

Volumn 23, Issue 10, 2001, Pages 1747-1772

  Perfetto, Eleanor M ^a   Mullins, C Daniel ^b   Subedi, Prasun ^c   Li McLeod, Josephine ^d  

^a Healthcentric Associates   (United States)

^b Center on Drugs and Public Policy   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d BAYER CORPORATION   (United States)

Author keywords

Bronchitis; Cost; Patient reported outcomes; Productivity; Quality of life; Work loss

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CEFDINIR; CEFETAMET PIVOXIL; CEFIXIME; CEFPROZIL; CEFTIBUTEN; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DIRITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LORACARBEF; MOXIFLOXACIN; OFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC THERAPY; CHRONIC BRONCHITIS; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE EXACERBATION; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; VALIDATION PROCESS;

EID: 0035159707     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80142-9     Document Type: Article

References (97)

1. Epidemiology of chronic airways disease
2. Treatment cost of acute exacerbations of chronic bronchitis
3. Direct medical costs of chronic obstructive pulmonary disease: Chronic bronchitis and emphysema
4. The patient's burden: Physical and psychological effects of acute exacerbations of chronic bronchitis
5. Epidemiology and pharmacoeconomic issues relating to acute respiratory tract infections and acute uncomplicated infections of the urinary tract
6. Are antibiotics effective treatment for acute bronchitis? A meta-analysis
7. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis
8. Workplace costs associated with acute exacerbation of chronic bronchitis: A comparison of moxifloxacin and levofloxacin
9. Acute exacerbations of chronic bronchitis: An international comparison
10. Acute bronchitis in adults: Commonly diagnosed but poorly defined
11. Antibiotics in acute bronchitis and exacerbations of chronic bronchitis: What is general practitioners' habit?
12. Role of infection in chronic bronchitis
13. How do we achieve cost-effective options in lower respiratory tract infection therapy?
14. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis
15. Acute bacterial exacerbations in bronchitis and asthma
16. Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis: A double-blind crossover study
17. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily
18. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis
19. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
20. Bacteriological eradication of Streptococcus pneumoniae from patients with acute exacerbations of chronic bronchitis: Cefuroxime axetil versus cefixime
21. Economic, clinical, and humanistic outcomes: A planning model for pharmacoeconomic research
22. The role of the ECHO model in outcomes research and clinical practice improvement
23. Methodology in behavioral and psychosocial cancer research. Conceptualizing disease impact and treatment outcomes
24. Convening health outcomes methodologists
25. Acceptable evidence for pharmaceutical advertising and labeling
26. Using outcomes research in clinical practice
27. Processes and outcomes of care for patients with community-acquired pneumonia: Results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study
28. Patient outcomes research teams: Contributions to outcomes and effectiveness research
29. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis
30. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d.
31. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis
32. Comparison of ceftibuten versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis
33. Cefaclor af versus amoxycillin/clavulanate in acute bacterial exacerbations of chronic bronchitis: A randomised multicentre study
34. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis
35. Amoxicillin/clavulanic acid vs cefetamet pivoxil in the treatment of acute exacerbation of chronic bronchitis (AECB) in adults
36. Comparative evaluation of the clinical and microbiological efficacy of coamoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis
37. Comparative study of dirithromycin and azithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis
38. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: The relationship with in-vitro activity
39. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: A multicenter, double-blind, randomized, comparative study
40. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis
41. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis
42. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis
43. Comparison of a 5-day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis
44. Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis
45. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis
46. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis
47. Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis
48. A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis
49. Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis
50. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis
51. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis
52. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: Sparfloxacin versus clarithromycin
53. Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis
54. Treatment of acute exacerbations of chronic bronchitis: Comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study
55. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis
56. Ofloxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbation of chronic bronchitis
57. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis
58. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: Results of a randomized, double-blind study
59. Efficacy and safety of cefdinir in the treatment of patients with acute bronchitis
60. International study comparing cefdinir and cefuroxime axetil in the treatment of patients with acute exacerbation of chronic bronchitis
61. Sequential therapy with cefuroxime followed by cefuroxime axetil in acute exacerbations of chronic bronchitis
62. Five-day dirithromycin therapy is as effective as seven-day erythromycin therapy for acute exacerbations of chronic bronchitis
63. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis
64. Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis
65. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults
66. Erythromycin in the treatment of acute bronchitis in a community practice
67. A comparative study of co-trimoxazole and amoxycillin in the treatment of acute bronchitis in general practice: A multicentre study
68. A placebo-controlled, double-blind trial of erythromycin in adults with acute bronchitis
69. The treatment of acute bronchitis with trimethoprim and sulfamethoxazole
70. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis
71. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year
72. Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis
73. Effectiveness of erythromycin in the treatment of acute bronchitis
74. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis
75. Doxycycline in acute bronchitis: A randomized double-blind trial
76. Azithromycin versus pivampicillin in the treatment of acute exacerbations of chronic bronchitis: A single-blind, double-dummy, multicentre study
77. Azithromycin compared with clarithromycin in the treatment of adult patients with acute purulent tracheobronchitis: A cost of illness study
78. Randomised controlled trial of antibiotics in patients with cough and purulent sputum
79. Dirithromycin versus amoxiclav in the treatment of acute exacerbations of chronic bronchitis
80. Acute bronchitis: Course of symptoms and restrictions in patients' daily activities
81. A randomized, controlled trial of doxycycline in the treatment of acute bronchitis
82. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis
83. Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bronchitis
84. Antibiotics in acute bronchitis: A meta-analysis
85. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis
86. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infections
87. Acute exacerbations of chronic bronchitis: Disease-specific issues that influence the cost-effectiveness of antimicrobial therapy
88. Antibiotics in chronic obstructive pulmonary disease exacerbations